Observational StudyImpact of hemodialysis solutions containing different levels of molecular hydrogen (H2) on the patient‑reported outcome of fatigueMHID-22983482022Renal Replacement TherapySusumu Uemura, Yoshitaka Kegasa, Keigo Tada, Taichi Tsukahara, Shigeru Kabayama, Tae Yamamoto, et al.Background: Reportedly, dialysis solutions containing molecular hydrogen (H2) might ameliorate patient-reported fatigue in hemodialysis (HD) patients. However, it is unknown whether its impact might differ with different H2 levels. Method: This single-arm, prospective observational study examined 105 patients on chronic HD (62 males; mean age, 66 years; mean HD duration, 117 months). All patients
Observational StudyHighlightedPossible clinical effects of molecular hydrogen (H2) delivery during hemodialysis in chronic dialysis patients: Interim analysis in a 12 month observationMHID-9655362PMID: 289029002017PLoS ONEMasaaki Nakayama, Noritomo Itami, Hodaka Suzuki, Hiromi Hamada, Naoyuki Osaka, Ryo Yamamoto, et al.Background and aim: It is supposed that enhanced oxidative stress and inflammation are involved with the poor clinical outcomes in patients on chronic dialysis treatment. Recent studies have shown that molecular hydrogen (H2) is biologically active as an anti-inflammatory agent. Thus, we developed a novel hemodialysis (E-HD) system which delivers H2 (30 to 80 ppb)-enriched dialysis solution, to co
